We encourage our employees to dream

Then we give them the freedom to reach those dreams

Otsuka

We create innovations for the WORLD

Our Products

Otsuka Canada Pharmaceutical Inc. (OCPI) is an innovative, fast-growing health care company that commercializes Otsuka medicines in Canada, with a focus on commitment to neuroscience, and nephrology. OCPI is dedicated to improving patients’ health and the quality of human life.

^PrABILIFY® (aripiprazole)

^PrABILIFY MAINTENA® (aripiprazole)

^PrJINARC® (tolvaptan)

^PrKORSUVA® (difelikefalin injection)

^PrREXULTI® (brexpiprazole)

^PrSAMSCA® (tolvaptan)

^PrTAVNEOS® (avacopan)

^PrVELPHORO® (sucroferric oxyhydroxide)

^PrVELTASSA® (patiromer)

Careers

Start a new Story at Otsuka

Come and work with a team of people who aren’t afraid to challenge convention. This approach can lead to something new, something better.

We aspire to attract best-in-class people and partners. After all, having the right team makes all the difference.

We encourage our employees to dream. Then we give them the freedom to reach for those dreams.

What is your story going to be?

VIEW ALL CAREERS

News

August 16, 2022

Otsuka Canada Pharmaceutical Inc. announces Health Canada approval of KORSUVA® (difelikefalin) for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult hemodialysis patients

MONTREAL, Aug. 16, 2022 /CNW/ – Otsuka Canada Pharmaceutical Inc. (OCPI) today announced that Health Canada has approved KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis.1 KORSUVA is a first-in-class kappa opioid receptor (KOR) agonist that targets the body’s peripheral nervous system. CKD associated pruritus affects an estimated 16,000 Canadians with end-stage renal disease on hemodialysis.^2,3